<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Psychiatry Investig</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychiatry Investig</journal-id>
<journal-id journal-id-type="publisher-id">PI</journal-id>
<journal-title-group>
<journal-title>Psychiatry Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">1738-3684</issn>
<issn pub-type="epub">1976-3026</issn>
<publisher>
<publisher-name>Korean Neuropsychiatric Association</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29209390</article-id>
<article-id pub-id-type="pmc">5714728</article-id>
<article-id pub-id-type="doi">10.4306/pi.2017.14.6.844</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Mechanism of Anti-Epileptogenesis by Levetiracetam Treatment is Similar to the Spontaneous Recovery of Idiopathic Generalized Epilepsy during Adolescence</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kikuyama</surname>
<given-names>Hiroki</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hanaoka</surname>
<given-names>Tadahito</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kanazawa</surname>
<given-names>Tetsufumi</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yoshida</surname>
<given-names>Yasushi</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mizuno</surname>
<given-names>Takafumi</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Toyoda</surname>
<given-names>Hirotaka</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yoneda</surname>
<given-names>Hiroshi</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
</contrib-group>
<aff id="A1">Department of Neuropsychiatry, Osaka Medical College, Osaka, Japan.</aff>
<author-notes>
<corresp>Correspondence: Hiroki Kikuyama, MD. Department of Neuropsychiatry, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan. Tel: +81-726-83-1221, Fax: +81-726-83-4810, <email>kikuyama@osaka-med.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>11</month>
<year>2017</year>
</pub-date>
<volume>14</volume>
<issue>6</issue>
<fpage>844</fpage>
<lpage>850</lpage>
<history>
<date date-type="received">
<day>05</day>
<month>10</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>24</day>
<month>11</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 Korean Neuropsychiatric Association</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Korean Neuropsychiatric Association</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>The anti-epileptogenic drug levetiracetam has anticonvulsant and anti-epileptogenesis effects. Synergy between cell death and inflammation can lead to increased levels of apoptosis inhibitory factors and brain-derived neurotrophic factor, aberrant neurogenesis and extended axon sprouting. Once hyperexcitation of the neural network occurs, spontaneous seizures or epileptogenesis develops. This study investigated whether the anti-epileptogenic effect of levetiracetam is due to its alternate apoptotic activity.</p>
</sec>
<sec>
<title>Methods</title>
<p>Adult male Noda epileptic rats were treated with levetiracetam or vehicle control for two weeks. mRNA quantification of Bax, Bcl-2 and GAPDH expression were performed from prefrontal cortex and hippocampus tissue samples.</p>
</sec>
<sec>
<title>Results</title>
<p>The levetiracetam-treated group showed a significant increase of Bax/Bcl-2 mRNA expression ratio in the prefrontal cortex than the control group, but no change in the Bax/Bcl-2 mRNA expression ratio in hippocampus.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Idiopathic generalized epilepsy including childhood absence epilepsy develop at childhood and recover spontaneously during adolescence. The aberrant neural excitable network is pruned by a neural-maturing action. This study suggests the mechanism of acquired anti-epileptogenesis by levetiracetam treatment may be similar to spontaneous recovery of idiopathic generalized epilepsy during adolescence.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Levetiracetam</kwd>
<kwd>Apoptosis</kwd>
<kwd>Epileptogenesis</kwd>
<kwd>Idiopathic generalized epilepsy</kwd>
<kwd>Noda epileptic rat</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Idiopathic generalized epilepsy, such as childhood absence epilepsy, develop at childhood and recover spontaneously during puberty, patients with other types of epilepsy are often prescribed medicine throughout their lifetime. Available anticonvulsant drugs may prevent seizures, but do not cure epileptogenesis.<xref ref-type="bibr" rid="B1">1</xref><xref ref-type="bibr" rid="B2">2</xref> The antiepileptic action of most anticonvulsants acts on ion-channels. Many ion-channel related genes have been identified as susceptibility genes for epilepsy.<xref ref-type="bibr" rid="B3">3</xref> Although seizures are inhibited during anticonvulsant treatment, they can occur again following cessation of treatment. Therefore, the action of ion-channels is related to the seizure, but not to epileptogenesis itself.<xref ref-type="bibr" rid="B4">4</xref> It was previously suggested that regulation of ion-channels and neurotransmitters involved an anti-ictogenic action, whereas neurotransmitters, neurotrophins, apoptosis, or nitric oxide synthase may contribute to the anti-epileptogenic effect.<xref ref-type="bibr" rid="B4">4</xref> In temporal lobe epilepsy (TLE), a type of symptomatic localization-related epilepsy, evidence increasingly suggests that changes in the neural network are involved in acquiring epileptogenesis because of the limited focus region in the inner surface of the temporal lobe, such as the hippocampus. Decreased volume of the hippocampus due to neuronal loss is known as hippocampal sclerosis. In addition, the neurogenesis of ectopic granular cells occurs concurrently with neuronal death, and aberrant axonal sprouting (mossy fibers) are observed in the brain.<xref ref-type="bibr" rid="B5">5</xref> The principal mechanism of epileptogenesis is due to the excitability of the neural network, both by ectopic neurons or axons.<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6">6</xref> The Bcl-family, known modulators of apoptosis, and neurotrophins may be related to aberrant neurogenesis and extended axons. Indeed, apoptosis inhibitory factors such as brain-derived neurotrophic factor (BDNF),<xref ref-type="bibr" rid="B7">7</xref> Bcl-2 and Bcl-XL,<xref ref-type="bibr" rid="B8">8</xref> were increased in the postmortem brain of patients with TLE associated with hippocampal sclerosis.</p>
<p>Symptomatic localization-related epilepsy can develop after the occurrence of brain infarction, head trauma, head surgery, Alzheimer's disease, or encephalitis. During brain infarction or head trauma, injured neurons secrete adenosine triphosphate (ATP). Discharged ATP subsequently activates microglia, cells which monitor the behavior of neurons, which then secrete inflammatory cytokines, such as IL-1β, which can induce an inflammatory repair response.<xref ref-type="bibr" rid="B9">9</xref><xref ref-type="bibr" rid="B10">10</xref> In Alzheimer's disease, accumulated amyloid-β can behave as an inflammasome,<xref ref-type="bibr" rid="B11">11</xref> and induce inflammation as an innate immune defense of the brain.<xref ref-type="bibr" rid="B12">12</xref><xref ref-type="bibr" rid="B13">13</xref> In addition, increased inflammatory mediators such as IL-1β are observed in Rasmussen encephalitis. Moreover, intractable seizures can be cured by treatment with ACTH, steroids, immunoglobulins, plasmapheresis and immunosuppressants, suggesting a relationship between inflammation, seizures, and epileptogenesis.<xref ref-type="bibr" rid="B14">14</xref> Animal models of epilepsy are induced by injecting kainic acid into the brain. Kainic acid induces cell death, and the subsequent release of ATP from dead cells activates microglia to produce IL-1β that activates astrocytes. Alpha-2 macroglobulin secreted from activated astrocytes induces the extension of neuronal axons, and repairs damaged neurons. In addition, apoptosis may promote neurogenesis.<xref ref-type="bibr" rid="B15">15</xref> The EL mouse,<xref ref-type="bibr" rid="B16">16</xref> a natural model of epilepsy, develops epileptogenesis with spontaneous seizures from 10 weeks of age. Apoptosis related factors, neurotrophin,<xref ref-type="bibr" rid="B17">17</xref> inflammatory cytokines<xref ref-type="bibr" rid="B18">18</xref> and cell cycle components<xref ref-type="bibr" rid="B19">19</xref> are significantly altered at the time of epileptogenesis. In addition, Bcl-2, and BDNF levels are increased. However, cytokine levels return to the baseline, and cell cycling is normalized at 24 weeks of age in the EL mouse.</p>
<p>Synergy between cell death and inflammation increases levels of apoptosis inhibitory factors and BDNF, induces aberrant neurogenesis and extension of axons, and eventually leads to a hyper excitable neural network which causes epileptogenesis. Previous studies suggest that epileptic seizures promote apoptosis and increase BDNF levels.<xref ref-type="bibr" rid="B20">20</xref> Thus these sensitization phenomena may promote epileptogenesis. Functional genomic analysis by microarray demonstrated significant changes in gene expression related to cell death, acute inflammatory responses, and synaptic vesicles.<xref ref-type="bibr" rid="B21">21</xref> Synaptic Vesicle 2A (SV2A) is a component factor of the synaptic vesicle, and exocytosis of neurotransmitters from vesicles is decreased in SV2A deficient mice.<xref ref-type="bibr" rid="B22">22</xref> It has been reported that SV2A is decreased both in postmortem brains with TLE<xref ref-type="bibr" rid="B23">23</xref> and epilepsy-associated brain tumors.<xref ref-type="bibr" rid="B24">24</xref></p>
<p>Levetiracetam is a pyrrolidone derivative, and used as an anticonvulsant,<xref ref-type="bibr" rid="B25">25</xref> which does not mediate its effects through neurotransmitters (glutaminergic acid, GABA, dopamine, serotonin) or ion-channel proteins,<xref ref-type="bibr" rid="B26">26</xref> but is linked to SV2A.<xref ref-type="bibr" rid="B27">27</xref> Since the efficacy of levetiracetam is decreased in SV2A-deficient mice, it is likely that the clinical efficacy of this compound is related to the modulation of neurotransmitters via SV2A.<xref ref-type="bibr" rid="B22">22</xref> Levetiracetam has been shown to have both anticonvulsant efficacy and antiepileptogenic action in animal models, such as the spontaneous epileptic rat (SER).<xref ref-type="bibr" rid="B2">2</xref> SER was established as a double mutant by crossing tremor rats and zitter rats. SER were pretreated with levetiracetam before developing epileptogenesis to maintain anticonvulsant efficacy when stopping levetiracetam treatment, as seizures have been observed immediately after discontinuing treatment with other anticonvulsants,<xref ref-type="bibr" rid="B28">28</xref> In addition, pre-treatment may decrease the number and duration of seizures, even after stopping the levetiracetam treatment.<xref ref-type="bibr" rid="B29">29</xref> It has been reported that the progression of kindling was markedly delayed in levetiracetam-pretreated amygdala kindling rats due to the inhibition of increasing levels of BDNF.<xref ref-type="bibr" rid="B30">30</xref> It may be predicted that Bcl-2 expression is also inhibited if levetiracetam inhibits BDNF, as the antiepileptogenic action of levetiracetam is due to the decreased expression of BDNF and Bcl-2. However, as the ratio of Bax/Bcl-2 expression levels is an indispensable biomarker for the inhibition of apoptosis, the primary endpoint for the current study was the ratio of Bax/Bcl-2 mRNA expression in the prefrontal cortex and hippocampus after levetiracetam treatment of Noda epileptic rats (NER). NER is a natural model of Epilepsy, spontaneous convulsions are controlled by autosomal recessive gene for epilepsy, therefore, they are comparable to generalized epilepsy for humans.<xref ref-type="bibr" rid="B31">31</xref></p>
</sec>
<sec sec-type="methods">
<title>METHODS</title>
<sec>
<title>Animals and drug administration procedure</title>
<p>Adult male Noda epileptic rats aged 5 weeks were housed under a 12-h light-dark cycle at a temperature of 19–20℃ with free access to both food and water. All procedures involving animals were performed in accordance with Animal Care Guidelines and approved by the Osaka Medical College Committee on Animal Care and Supply. After 1 week of acclimatization, rats were divided into two groups (n=6 per group). The rats were given daily inter-peritoneal (i.p.) drug injections for two weeks. Group 1 received levetiracetam (80 mg/kg) and group 2 received a vehicle control (0.9% saline).</p>
</sec>
<sec>
<title>RNA isolation and cDNA synthesis</title>
<p>Brains were dissected and placed on an ice-cold plate. The samples from the prefrontal cortex and hippocampus were rapidly dissected and immediately frozen in liquid nitrogen and stored at −80℃. Total RNAs were isolated from the tissues using a Qiagen RNeasy Minikit (Qiagen, Hilden, Germany), and subjected to first-strand cDNA synthesis with the reverse transcriptase (RT) OMNISCRIPT (Qiagen), using a random primer (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. A total RNA of 200ng (based on absorbance) was transcribed into cDNA and added to each reaction of the Quantitative RT-PCR assay.</p>
</sec>
<sec>
<title>Primers and probes</title>
<p>Quantification of the mRNA expression for Bax, Bcl-2 and GAPDH were performed using the LightCycler apparatus (Roche Diagnostics, Basel, Switzerland). Primers and probes used were designed with the assistance of Oligo 4.0 (National Biosciences, Plymouth, MN, USA) and synthesized by Nihon-Idenshiken (Sendai, Japan).</p>
</sec>
<sec>
<title>Construction of the plasmid calibrators</title>
<p>The transcripts that encode for Bcl-2, Bax and GAPDH were amplified by RT-PCR using specific primers. The PCR product of each gene was cloned into the pGEM T easy Vector (Promega, Madison, WI, USA) and sequenced. The standard curves were generated from serially diluted solutions of each plasmid clone as templates.</p>
</sec>
<sec>
<title>Data analysis</title>
<p>Statistical comparison of data from levetiracetam and sa-line-treated groups was performed using a two-tailed Student's t-test. A value of p&lt;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results">
<title>RESULTS</title>
<sec>
<title>Primary endpoint</title>
<p>The Levetiracetam-treated group showed a significant increase in Bax/Bcl-2 mRNA expression ratios from the prefrontal cortex compared with the control group (Mean±SD; 1.40±0.31 vs. 0.96±0.14 respectively, p=0.02) (<xref ref-type="fig" rid="F1">Figure 1</xref>). However, levetiracetam treatment did not alter the Bax/Bcl-2 mRNA expression ratio in the hippocampus compared with the control group (0.78±0.17 vs. 0.80±0.27 respectively, p=0.90).</p>
</sec>
<sec>
<title>Secondary endpoint</title>
<p>The levetiracetam-treated group showed an increase in Bcl-2 mRNA expression levels in the prefrontal cortex compared with the control group (relative values when the expression of GAPDH mRNA is regarded as 1,000; 8.7±2.5 vs. 6.2±1.8 respectively, p=0.08) (<xref ref-type="fig" rid="F2">Figure 2</xref>). Levetiracetam treatment did not alter Bax mRNA expression levels compared to the control group (8.2±0.8 vs. 8.1±1.0 respectively, p=1.00). In the hippocampus there was no differences in the mRNA expression level of Bax and Bcl-2 between the levetiracetam-treated and control groups (Bcl-2: 15.0±4.3 vs. 14.6±5.2 respectively, p=0.90; Bax: 11.2±2.0 vs. 10.6±0.9; respectively, p=0.48).</p>
</sec>
</sec>
<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>The current study observed increased Bax/Bcl-2 ratios at the prefrontal cortex in Noda epileptic rat, which likely contribute to a decrease of Bcl-2 rather than an increase in Bax levels. However, this association was only evaluated by analyzing mRNA expression of Bax and Bcl-2, whereas down-stream apoptosis exective factors such as caspases were not analyzed. In addition, we did not perform nuclear fragmentation analysis, a marker for apoptotic cell death, or monitor behavioral influences. Although our current findings should be regarded as preliminary, further study is required to determine the relationship between altered mRNA levels, expression of proteins, and fragmentation of the nucleus as apoptosis regulating/performance factors with the inhibition of seizures or anti-epileptogenesis effect. Furthermore, the Bax/Bcl-2 ratio was up-regulated in the prefrontal cortex of levetiracetam-treated rats, whereas it was not observed in the hippocampus. Compared with the Wistar rat, SV2A expression in the parietal-temporal cortex was significantly increased in Noda epileptic rats,<xref ref-type="bibr" rid="B32">32</xref> but not in the hippocampus. Levetiracetam is reported to have a diminished clinical efficacy on decreasing SV2A expression. Thus, levetiracetam may not have an effect on the apoptosis regulating factor in Noda epileptic rat hippocampus, as the SV2A expression level is same as normal rats. Although the volume and duration of levetiracetam-treatment was determined according to a previous study,<xref ref-type="bibr" rid="B28">28</xref> the anti-epileptogenesis effect of levetiracetam may be different in other strains of rat, and therefore the volume and duration used in this study were not optimized for the Noda epileptic rat. The transition of Bax/Bcl-2 expression required to induce anti-epileptogenesis in the EL mouse was previously reported, and the expression pattern differed between the frontal lobe cortex and hippocampus.<xref ref-type="bibr" rid="B17">17</xref> Further analysis is needed to assess the expression pattern of Bax, Bcl-2, Bcl-XL, and other apoptosis-regulating factors throughout the duration of the treatment.</p>
</sec>
<sec>
<title>The anti-epileptogenesis mechanism of levetiracetam</title>
<p>Focal cortical dysplasia is a brain malformation with hyperplasia in the cortex, which induces intractable epilepsy. The mechanism of cortex hyperplasia involves the inhibition of apoptosis, increased BDNF levels, and the formation of an aberrant neuronal network. Assessment of dysplastic cells from cortical dysplasia patients demonstrated that the expression of the NR2A subunit was decreased to a quarter of the control level, whereas the NR2B subunit was increased ten times, and therefore the NR2A/NR2B ratio was 1:40.<xref ref-type="bibr" rid="B33">33</xref></p>
<p>The NMDA receptor expression pattern is different according to the developmental stage of the brain. The main subunits are NR2A and NR2B, and the NR2A/NR2B ratio is low in in-fants and higher in adolescent years, whereas it becomes lower than adolescent at young adult years on human postmortem brain.<xref ref-type="bibr" rid="B34">34</xref> The NR2A subunit does not have a nitric oxide synthase (NOS)-binding site, although it is present in NR2B. NOS produces nitric oxids (NO), a type of gas, and therefore it can circulate easily throughout the brain and activate guanylate cyclase (GC) present in the surrounding brain cells.</p>
<p>The activity of GC is 50 times higher in NR2B than NR2A. GC is an enzyme which mediates GTP to cGMP transformation. cGMP activates protein kinase G (PKG), by phosphorylating Ser9 in glycogen synthase kinase-3 beta (GSK-3β) which inhibits activation of GSK-3β. GSK-3β is involved neuroprotective effect in the human brain, and its inhibition allows in-creased levels of BDNF and Bcl-2, which lead to inhibition of apoptosis, and the start of neurogenesis. Hyperplasia in the brain cortex during focal cortical dysplasia may be due to the excessive neuroprotective effect afforded by the diminished NR2A/NR2B ratio.<xref ref-type="bibr" rid="B33">33</xref> While the lower NR2A/NR2B ratio in infants is neuroprotective, the higher ratio in adolescents is regarded as neuropathic. The realignment of the immature brain is thought to be due to the pruning of unnecessary neural networks, to ensure the mature brain consists of only high-quality neurons. Therefore, the higher NR2A/NR2B ratio in adolescents is considered a neuron-maturing effect.</p>
<p>With idiopathic generalized epilepsy, such as childhood absence epilepsy, the illness spontaneously recovers during puberty. This may be due to an increased NR2A/NR2B ratio, which directs aberrant excitable neural networks to be pruned at that time. Neuroprotection or neuron-maturing is determined by the activation or suppression of GSK-3β. GSK-3β is neuroprotective when suppressed, but neuron-maturing when activated. GSK-3β is activated following phosphorylation at Tyr 216, or suppressed by phosphorylation at Ser 9. The default status of GSK-3β is activated. Without stimulation, or with an inappropriate input into the neuron, GSK-3β remains activated by autophosphorylation, and therefore the neuron will undergo apoptosis or sub-lethal apoptosis.<xref ref-type="bibr" rid="B35">35</xref> Conversely, the upstream kinase of GSK-3β can phosphorylate Ser9 and upon the appropriate input, the neuron will survive. The upstream cascade of GSK-3β contains cytokine pathways, G protein-coupled receptors (GPCR), ion channels, and the Wnt pathway (<xref ref-type="fig" rid="F3">Figure 3</xref>). Various input stimuli can activate GSK-3β and induce cell death. However, the range between appropriate or inappropriate input stimuli is different between diseases or ages (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p>
<p>During infancy, the range of input stimuli is judged as appropriate for neuroprotective efficiency due to the high NR2A/NR2B ratio. Conversely, neuron-maturing efficiency is increased during adolescence due to the changed range to judge the input stimuli as inappropriate (<xref ref-type="fig" rid="F4">Figure 4A</xref>). This may suggest why idiopathic generalized epilepsy spontaneously resolves during the realignment of the adolescent brain network. Simply, the aberrant neural excitable network is pruned by a neural-maturing action (<xref ref-type="fig" rid="F4">Figure 4B</xref>). When spontaneous recovery does not occur, it is likely that the neuron-maturing action has not been activated (<xref ref-type="fig" rid="F4">Figure 4C</xref>). The NR2A/NR2B ratio decreases again after adolescence and therefore idiopathic generalized epilepsy is not easily cured in adults if the aberrant neural excitable network is not pruned at adolescence.</p>
<p>Further discussion is warranted for the relationship between neurotransmitters and neuro-developmental action. It is thought that levetiracetam may change the volume of discharge of neurotransmitters from the pre-synaptic cell to the synaptic cleft through its action on SV2A. Neurotransmitters, such as dopamine and noradrenalin are known to be neuroprotective if the quantity of antipsychotic agents is a minimal,<xref ref-type="bibr" rid="B36">36</xref> although neurodeficiency will occur if it is excessive.<xref ref-type="bibr" rid="B37">37</xref> In epileptic patients, higher BDNF and Bcl-2 levels provide a neuroprotective effect similar to that seen in childhood, and therefore gives a wider range to evaluate the input stimuli as appropriate. Levels of neurotransmitters released from the pre-synaptic neuron are changed by levetiracetam-treatment and cause post-synaptic neurons to undergo neuro-maturation. This pruning of the aberrant excitable network exerts the anti-epileptogenesis effect of levetiracetam treatment (<xref ref-type="fig" rid="F4">Figure 4D</xref>). We therefore suggest that the mechanism of acquired anti-epileptogenesis by levetiracetam treatment is the same as the spontaneous recovery seen in idiopathic generalized epilepsy during adolescence. The current findings verify our assertions, although the process of GSK-3β activation following the volumetric alterations of neurotransmitter release within the synaptic cleft is not well established. Therefore further research is needed to determine which neurotransmitter and which receptor are involved in the process (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We are grateful to Dr. T. Nakagawa for his helpful advice and to UCB S. A. levetiracetam supply.</p>
</ack>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loscher</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Current status and future directions in the pharmacotherapy of epilepsy</article-title>
<source/>Trends Pharmacol Sci
          <year>2002</year>
<volume>23</volume>
<fpage>113</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">11879677</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasa</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A new frontier in epilepsy: novel antiepileptogenic drugs</article-title>
<source/>J Pharmacol Sci
          <year>2006</year>
<volume>100</volume>
<fpage>487</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="pmid">16799261</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armijo</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Shushtarian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Valdizan</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de las Cuevas</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Adin</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Ion channels and epilepsy</article-title>
<source/>Curr Pharm Des
          <year>2005</year>
<volume>11</volume>
<fpage>1975</fpage>
<lpage>2003</lpage>
<pub-id pub-id-type="pmid">15974971</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weaver</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Epileptogenesis, ictogenesis and the design of future antiepileptic drugs</article-title>
<source/>Can J Neurol Sci
          <year>2003</year>
<volume>30</volume>
<fpage>4</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">12619776</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koyama</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Fujisawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Katoh-Semba</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matsuki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ikegaya</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor induces hyperexcitable reentrant circuits in the dentate gyrus</article-title>
<source/>J Neurosci
          <year>2004</year>
<volume>24</volume>
<fpage>7215</fpage>
<lpage>7224</lpage>
<pub-id pub-id-type="pmid">15317847</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharfman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McCloskey</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Ectopic granule cells of the rat dentate gyrus</article-title>
<source/>Dev Neurosci
          <year>2007</year>
<volume>29</volume>
<fpage>14</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">17148946</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Selective Upregulation of Brain-derived Neurotrophic Factor (BDNF) Transcripts and BDNF Direct Induction of Activity Independent N-Methyl-D-aspartate Currents in Temporal Lobe Epilepsy Patients with Hippocampal Sclerosis</article-title>
<source/>J Int Med Res
          <year>2011</year>
<volume>39</volume>
<fpage>1358</fpage>
<lpage>1368</lpage>
<pub-id pub-id-type="pmid">21986136</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Engel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Henshall</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Apoptosis, Bcl-2 family proteins and caspases: the ABCs of seizure-damage and epileptogenesis?</article-title>
<source/>Int J Physiol Pathophysiol Pharmacol
          <year>2009</year>
<volume>1</volume>
<fpage>97</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="pmid">21383882</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>John</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Rivieccio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brosnan</surname>
<given-names>CF</given-names>
</name>
</person-group>
<article-title>IL-1-regulated responses in astrocytes: relevance to injury and recovery</article-title>
<source/>Glia
          <year>2005</year>
<volume>49</volume>
<fpage>161</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="pmid">15472994</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kono</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rock</surname>
<given-names>KL</given-names>
</name>
</person-group>
<article-title>How dying cells alert the immune system to danger</article-title>
<source/>Nat Rev Immunol
          <year>2008</year>
<volume>8</volume>
<fpage>279</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="pmid">18340345</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schroder</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The inflammasomes</article-title>
<source/>Cell
          <year>2010</year>
<volume>140</volume>
<fpage>821</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="pmid">20303873</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenstein</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetics: finding risk factors</article-title>
<source/>Nature
          <year>2011</year>
<volume>475</volume>
<fpage>S20</fpage>
<lpage>S22</lpage>
<pub-id pub-id-type="pmid">21760580</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rock</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Latz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ontiveros</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kono</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The sterile inflammatory response</article-title>
<source/>Annu Rev Immunol
          <year>2010</year>
<volume>28</volume>
<fpage>321</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="pmid">20307211</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vezzani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Balosso</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maroso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zardoni</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Noe</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ravizza</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy</article-title>
<source/>Curr Opin Investig Drugs
          <year>2010</year>
<volume>11</volume>
<fpage>43</fpage>
<lpage>50</lpage>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryoo</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Gorenc</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Steller</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Apoptotic cells can induce compensatory cell proliferation through the JNK and the Wingless signaling pathways</article-title>
<source/>Dev Cell
          <year>2004</year>
<volume>7</volume>
<fpage>491</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="pmid">15469838</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meidenbauer</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Mantis</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Seyfried</surname>
<given-names>TN</given-names>
</name>
</person-group>
<article-title>The EL mouse: a natural model of autism and epilepsy</article-title>
<source/>Epilepsia
          <year>2011</year>
<volume>52</volume>
<fpage>347</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="pmid">21204822</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murashima</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yoshii</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Developmental program of epileptogenesis in the brain of EL mice</article-title>
<source/>Epilepsia
          <year>2005</year>
<volume>46</volume>
<issue>Suppl 5</issue>
<fpage>10</fpage>
<lpage>16</lpage>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murashima</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yoshii</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Role of cytokines during epileptogenesis and in the transition from the interictal to the ictal state in the epileptic mutant EL mouse</article-title>
<source/>Gene Regul Syst Bio
          <year>2008</year>
<volume>2</volume>
<fpage>267</fpage>
<lpage>274</lpage>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murashima</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yoshii</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cell cycle reentry and cell proliferation as candidates for the seizure predispositions in the hippocampus of EL mouse brain</article-title>
<source/>Epilepsia
          <year>2007</year>
<volume>48</volume>
<issue>Suppl 5</issue>
<fpage>119</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="pmid">17910591</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bozzi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dunleavy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Henshall</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Cell signaling underlying epileptic behavior</article-title>
<source/>Front Behav Neurosci
          <year>2011</year>
<volume>5</volume>
<fpage>45</fpage>
<pub-id pub-id-type="pmid">21852968</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Laurent</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Kostka</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ulitsky</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulatory networks define phenotypic classes of human stem cell lines</article-title>
<source/>Nature
          <year>2008</year>
<volume>455</volume>
<fpage>401</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="pmid">18724358</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaminski</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Gillard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leclercq</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hanon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lorent</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dassesse</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam</article-title>
<source/>Epilepsia
          <year>2009</year>
<volume>50</volume>
<fpage>1729</fpage>
<lpage>1740</lpage>
<pub-id pub-id-type="pmid">19486357</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Vliet</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Redeker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gorter</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy</article-title>
<source/>Epilepsia
          <year>2009</year>
<volume>50</volume>
<fpage>422</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="pmid">18717715</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Groot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toering</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Boer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Spliet</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Heimans</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Aronica</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex</article-title>
<source/>Neuro Oncol
          <year>2010</year>
<volume>12</volume>
<fpage>265</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="pmid">20167814</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulze-Bonhage</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Brivaracetam for the treatment of epilepsy</article-title>
<source/>Expert Opin Pharmacother
          <year>2011</year>
<volume>12</volume>
<fpage>1959</fpage>
<lpage>1966</lpage>
<pub-id pub-id-type="pmid">21682662</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gillard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matagne</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Henichart</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Wulfert</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes</article-title>
<source/>Eur J Pharmacol
          <year>1995</year>
<volume>286</volume>
<fpage>137</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="pmid">8605950</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Lambeng</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nocka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kensel-Hammes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bajjalieh</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Matagne</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2004</year>
<volume>101</volume>
<fpage>9861</fpage>
<lpage>9866</lpage>
<pub-id pub-id-type="pmid">15210974</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji-qun</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ishihara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nagayama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Serikawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sasa</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs</article-title>
<source/>Epilepsia
          <year>2005</year>
<volume>46</volume>
<fpage>1362</fpage>
<lpage>1370</lpage>
<pub-id pub-id-type="pmid">16146430</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Ji-qun</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ishihara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nagayama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Serikawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sasa</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER)</article-title>
<source/>Epilepsia
          <year>2005</year>
<volume>46</volume>
<fpage>1170</fpage>
<lpage>1177</lpage>
<pub-id pub-id-type="pmid">16060925</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Husum</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bolwig</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mathe</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties</article-title>
<source/>Epilepsy Behav
          <year>2004</year>
<volume>5</volume>
<fpage>204</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="pmid">15123022</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hashizume</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maihara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tomizawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NER rat strain: a new type of genetic model in epilepsy research</article-title>
<source/>Epilepsia
          <year>1998</year>
<volume>39</volume>
<fpage>99</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">9578020</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="confproc">
<person-group person-group-type="author">
<name>
<surname>Okumura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ishihara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kitataku</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tokudome</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<source/>Expression analysis of SV2A and SNARE-related proteins in Noda epileptic rat (NER), a rat model of generalized tonic-clonic seizure
          <conf-name>Joint congress of the 21st congress of Japanese society of clinical neuropsychopharmacology and the 41st annual meeting of Japanese society of neuropsychopharmacology</conf-name>
<conf-loc>Tokyo, Japan</conf-loc>
<year>2011</year>
<fpage>178</fpage>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crino</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Duhaime</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Baltuch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>White</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Differential expression of glutamate and GABA-A receptor subunit mRNA in cortical dysplasia</article-title>
<source/>Neurology
          <year>2001</year>
<volume>56</volume>
<fpage>906</fpage>
<lpage>913</lpage>
<pub-id pub-id-type="pmid">11294928</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Law</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Weickert</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Kleinman</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Expression of NMDA receptor NR1, NR2A and NR2B subunit mRNAs during development of the human hippocampal formation</article-title>
<source/>Eur J Neurosci
          <year>2003</year>
<volume>18</volume>
<fpage>1197</fpage>
<lpage>1205</lpage>
<pub-id pub-id-type="pmid">12956718</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jope</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Roh</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions</article-title>
<source/>Curr Drug Targets
          <year>2006</year>
<volume>7</volume>
<fpage>1421</fpage>
<lpage>1434</lpage>
<pub-id pub-id-type="pmid">17100582</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noh</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>EY</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Gwag</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Neurotoxic and neuroprotective actions of catecholamines in cortical neurons</article-title>
<source/>Exp Neurol
          <year>1999</year>
<volume>159</volume>
<fpage>217</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="pmid">10486189</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qing</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>XM</given-names>
</name>
</person-group>
<article-title>The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis</article-title>
<source/>Eur J Neurosci
          <year>2003</year>
<volume>17</volume>
<fpage>1563</fpage>
<lpage>1570</lpage>
<pub-id pub-id-type="pmid">12752374</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Expression ratio of Bax/Bcl-2 mRNA (primary endpoint). A: Prefrontal cortex. B: Hippocampus.</title>
</caption>
<graphic xlink:href="pi-14-844-g001"></graphic>
</fig>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>Expression level of Bax or Bcl-2 mRNA (secondary endpoint). A: Bcl-2 mRNA expression level in prefrontal cortex. B: Bax mRNA expression level in prefrontal cortex. C: Bcl-2 mRNA expression level in hippocampus. D: Bax mRNA expression level in hippocampus.</title>
</caption>
<graphic xlink:href="pi-14-844-g002"></graphic>
</fig>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<title>The intracellular signal transduction course which it is assumed to be associated with SV2A accommodation and nervous system maturity action of Levetiracetam. Arrow: promotion, T shape bar: inhibition, Red color: activated, Blue color: hypofunction. AC: adenylyl cyclase, ATP: adenosine triphosphate, BDNF: brain-derived neurotrophic factor, cAMP: cyclic adenosine monophosphate, CaM: calmodulin, cGMP: cyclic guanosine monophosphate, CN: calcineurin, CREB: cAMP response element binding protein, Cyt C: cytochrome c, DISC1: disrupted schizophrenia 1, DVL: mammalian homologue of drosophila dishevelled, EGF: epidermal growth factor, GC: guanylyl cyclase, GTP: guanosine triphosphate, FZD: frizzled, GSK3β: glycogen synthase kinase 3β, GPCR: G protein-coupled receptor, IL-2: interleukin 2, LRP: LDL-receptor-related protein, NFAT: nuclear factor of activated T cells, NO: nitric oxidase, NOS: nitric oxidase synthase, PDE: phospho-di-esterase, PDK1: phosphatidylinositide-dependent kinase 1, PD-1: programmed deth 1, PI3K: phosphatidylinositol 3 kinase, PKA: protein kinase A, PKC: protein kinase C, PKG: protein kinase G, PLC: phospholipase C, TCF: T-cell factor.</title>
</caption>
<graphic xlink:href="pi-14-844-g003"></graphic>
</fig>
<fig id="F4" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<title>Hypothesis: the mechanism of anti-epileptogenesis of levetiracetam is same as the spontaneous recovery of idiopathic generalized epilepsy during the adolescent period.</title>
</caption>
<graphic xlink:href="pi-14-844-g004"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>